GLPwatch
Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine
NCT01089569 · Completed
Last updated 2026-05-28This clinical trial tested whether using an exenatide injection twice daily or insulin glargine could help manage blood sugar levels in adults with type 2 diabetes.
Status Completed The study has finished.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 60 people
Who can join Ages 18–75 · all sexes
Timeline Started 2010-04 · est. completion 2013-05
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT01089569 ↗
Description as written by the study sponsor.
The primary purpose of this study is to compare the effect on 24-hour blood glucose patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a combination of insulin glargine and exenatide to metformin.
Treatments tested
- Exenatide also known as Bydureon Drug
5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
- Insulin Glargine also known as Lantus Drug
.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
| Main thing measured | HbA1c Change |
|---|---|
| Sponsor | HealthPartners Institute |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01089569 ↗